GSA Capital Partners’s Cytokinetics CYTK Stock Holding History

GSA Capital Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,165	Closed	-$348K	–	1683
2023 Q4	$348K	Buy	+4,165	New	+$151K	0.03%	1028
2022 Q4	–	Sell	-5,748	Closed	-$278K	–	1552
2022 Q3	$278K	Buy	+5,748	New	+$277K	0.04%	982
2021 Q4	–	Sell	-38,942	Closed	-$1.39M	–	1472
2021 Q3	$1.39M	Buy	+38,942	New	+$1.15M	0.14%	156
2020 Q1	–	Sell	-72,066	Closed	-$765K	–	1157
2019 Q4	$765K	Buy	+72,066	New	+$740K	0.09%	365
2017 Q4	–	Sell	-12,900	Closed	-$187K	–	1604
2017 Q3	$187K	Buy	+12,900	New	+$176K	0.01%	1466
2017 Q2	–	Sell	-131,502	Closed	-$1.69M	–	1725
2017 Q1	$1.69M	Buy	+131,502	New	+$1.54M	0.09%	332
2016 Q1	–	Sell	-117,931	Closed	-$1.23M	–	1716
2015 Q4	$1.23M	Buy	117,931 +99,287	+533%	+$974K	0.06%	546
2015 Q3	$125K	Buy	+18,644	New	+$127K	0.01%	1639
2015 Q2	–	Sell	-167,074	Closed	-$1.13M	–	1979
2015 Q1	$1.13M	Buy	+167,074	New	+$1.25M	0.05%	765

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

GSA Capital Partners's CYTK Position: Q1 2024 in Review

GSA Capital Partners sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 4,165 shares — an estimated $348K sold.

GSA Capital Partners first reported a position in CYTK in Q1 2015 and held it in 9 quarters. The position peaked at $1.69M in Q1 2017. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

GSA Capital Partners reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
GSA Capital Partners sold 4,165 Cytokinetics shares in Q1 2024, an estimated $348K.
GSA Capital Partners first reported a position in Cytokinetics in Q1 2015 and held it in 9 quarters.
GSA Capital Partners's Cytokinetics position peaked at $1.69M in Q1 2017.
390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on GSA Capital Partners's 13F filing for Q1 2024, filed 3 May 2024.